Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alexandre Karras1

  • 1Service de néphrologie, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20 rue Leblanc, 75015 Paris, France; Université Paris Cité, 85 boulevard Saint-Germain, Paris, France.

Nephrologie & Therapeutique
|December 30, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug interaction between maribavir and rifampin: a case report.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Kidney international·2026
Same author

Outcomes and Validation of Histopathological Scores in Pediatric ANCA-vasculitis.

Kidney international reports·2026
Same author

Thrombotic Microangiopathy, Cryoglobulinemia, and Acute Kidney Injury in Patients With Monoclonal Gammopathy: A Case Series.

American journal of hematology·2026
Same author

Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.

Kidney international reports·2026
Same author

Immune Profiling Identifies High-Risk Neutrophil-Rich Subtype in Checkpoint Inhibitor Nephritis.

Kidney international reports·2026
Same journal

Supporting patients and family members facing treatment choices in chronic kidney disease: What do professionals think of the decision aids used? - Professionals’ views on treatment decision support tools

Nephrologie & therapeutique·2026
Same journal

From Turing to ChatGPT: The origins and transformations of medical artificial intelligence

Nephrologie & therapeutique·2026
Same journal

Analysis of the predictive value of serum Cys-C and IL-6 levels for acute kidney injury in patients with acute respiratory distress syndrome.

Nephrologie & therapeutique·2026
Same journal

Navigating pain in chronic kidney disease: Overcoming inertia!

Nephrologie & therapeutique·2026
Same journal

Kidney health for all: caring for people, protecting the planet1.

Nephrologie & therapeutique·2026
Same journal

When the heart breaks, the kidneys follow: A case of Takotsubo syndrome

Nephrologie & therapeutique·2026
See all related articles

Avacopan, a C5a receptor inhibitor, offers a corticosteroid-sparing option for ANCA-associated vasculitis (AAV) induction therapy. This treatment improves renal function without increasing infection risk in AAV patients.

Area of Science:

  • Immunology
  • Nephrology
  • Rheumatology

Context:

  • The complement system, particularly C5a, is implicated in ANCA-associated vasculitis (AAV) pathophysiology.
  • Avacopan is an oral C5a receptor inhibitor developed to target this pathway.
  • Previous studies showed promising results in animal models and early human trials.

Purpose:

  • To evaluate avacopan as a corticosteroid-sparing agent in AAV induction therapy.
  • To assess the efficacy and safety of avacopan in combination with standard immunosuppressants.
  • To determine the impact on renal function and infectious complications.

Summary:

  • A phase 3 trial demonstrated avacopan can replace corticosteroids in AAV induction therapy alongside cyclophosphamide or rituximab.
  • This novel approach did not elevate infectious risks.
Keywords:
ANCAAvacopanComplementComplémentVasculariteVasculitis

Related Experiment Videos

  • Avacopan showed enhanced improvement in renal function during initial treatment for renal vasculitis.

    • Impact:

    • Avacopan's registration provides a new therapeutic option for AAV.
    • This represents a significant advancement in managing this autoimmune disease.
    • The drug offers a safer and potentially more effective induction therapy for AAV patients, especially those with renal involvement.